CTBO (Cantabio Pharmaceuticals) Short-Term Debt: $1.41 Mil (As of Dec. 2018)


What is Cantabio Pharmaceuticals Short-Term Debt?

Cantabio Pharmaceuticals CTBO Short-Term Debt is $1.41 Mil as of Dec. 2018.

Cantabio Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2018 was $1.41 Mil.

Cantabio Pharmaceuticals's quarterly Short-Term Debt declined from Jun. 2018 ($1.67 Mil) to Sep. 2018 ($1.64 Mil) and declined from Sep. 2018 ($1.64 Mil) to Dec. 2018 ($1.41 Mil).

Cantabio Pharmaceuticals's annual Short-Term Debt increased from Mar. 2016 ($0.00 Mil) to Mar. 2017 ($0.37 Mil) and increased from Mar. 2017 ($0.37 Mil) to Mar. 2018 ($1.21 Mil).

Cantabio Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cantabio Pharmaceuticals Short-Term Debt Related Terms

Cantabio Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Short-Term Debt Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.37 1.21

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 1.21 1.67 1.64 1.41
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $1.41 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Short-Term Debt of $1.41 Mil as of Dec. 2018.
Is Cantabio Pharmaceuticals' Short-Term Debt too high?
Cantabio Pharmaceuticals' current Short-Term Debt is $1.41 Mil.
How does Cantabio Pharmaceuticals' Short-Term Debt compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Short-Term Debt of $1.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cantabio Pharmaceuticals's current Short-Term Debt is $1.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Short-Term Debt of $1.41 Mil. The current Short-Term Debt is $1.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Short-Term Debt is $1.41 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.